Venus Remedies is a contract manufacturer of oncological and cefelosporine injectable products following EU-GMP norms. It has 2 manufacturing locations in India and one in Germany.
Recent Australia, Ukraine patents for drug Potentox, Vancoplus patent from South Africa and New Zealand, Tobracef patent in South Africa in 2009, a 5% rise in EPS in quarter ending Sep 10, a P/E of only around 5.00, plan to buy a plant in US and manufacture their branded antibiotic products there by end of 2011 seems like a dream come true.
The next few years will see a variety of new diseases surfacing around the world and we need powerful antibiotics to fight them. Potentox, combines the powerful antibiotics cephalosporin with aminoglycoside is a super specialty product indicated for the treatment of hospital acquired pneumonia, community acquired pneumonia and febrile neutropenia.
Vancoplus is a brand of Ceftriaxone and Vancomycin along with chemical vector used in CVMC technology which has a potential to restrict production of toxin produced by MRSA (Methilicillin Resistant Staphylococcus Aureus), the most notorious and troublesome pathogen. Vancoplus is the only remedy after vaccination to treat MRSA and multi-drug resistant microbes causing meningitis, pneumonia, typhoid, septicemia, urinary tract Infection, skin and skin structure infections and Staphylococcal endocarditis. Vancoplus has been successfully launched in few markets globally and has achieved a sales of US$3.5 mn in 3 years. The patent for VANCOPLUS is valid till February 2026 in both the countries. The patent of this product has also been filed in US, Canada, Europe, Ukraine, Russia etc besides India and the grant is expected to be received soon.
In August 2009, Venus Remedies got another Product Patent for Tobracef from the Companies and Intellectual Property Registration Office (CIPRO), South Africa. Tobracef is indicated for the treatment of complicated mixed bacterial infection of acute pulmonary exacerbations, cystic fibrosis, chronic obstructive pulmonary disease, an FDC cephalosporin and aminoglycoside. Tobracef also is under process of registration in many regulated and semi – regulated markets.
Buy Venus Remedies (BSE: 526953, NSE: VENUSREM) at 255-258 for a 2 month target of 325 (+26%). 1 year (Jan 2012) target is 400 (+55%).
No comments:
Post a Comment